We’re pleased to announce a new notice of special interest (NOSI) (NOT-GM-21-050) to address the urgent need for documenting COVID-19-related outcomes of patients, including those suffering from health disparities, which helps foster COVID-19-related clinical research. Competitive revisions to active IDeA-CTR (U54) awards will be considered for the purpose of sustaining and strengthening the IDeA state COVID-19 patient registry, a component of the National COVID Cohort Collaborative.

Applications are due by June 18, 2021. If you have any questions about this NOSI, please contact Hongwei Gao.

We’re pleased to announce the availability of supplements to active INBRE (P20), COBRE (P20, P30), IDeA-CTR (U54), and NARCH (S06) awards for sequencing-based surveillance studies of the SARS-CoV-2 virus to track variants circulating in communities the IDeA and NARCH programs serve. The supplements will support SARS-CoV-2 viral genome sequencing and analysis studies. Projects are expected to expand on or collaborate with ongoing SARS-CoV-2 testing studies or programs in order to leverage resources and deliver results quickly to help address the urgent challenge.

Applications are due by March 31, 2021; see NOT-GM-21-031 for additional details.

If you have any questions about this supplement opportunity, please contact me.

If you’re preparing an Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR) grant application for the October 7 receipt date, don’t miss our upcoming webinar:

Thursday, August 6, 3:00-4:30 p.m. ET

During the webinar, IDeA program staff will answer your questions about changes in the goals, objectives, and organizational structures of the IDeA-CTR program, as described in the funding opportunity announcement. Principal investigators who plan to submit new or renewal applications are encouraged to attend.

We’re pleased to announce that the Centers of Biomedical Research Excellence (COBRE) Phase 3 funding opportunity announcement (FOA) (PAR-20-115) has been reissued.

COBRE supports thematic, multidisciplinary research centers that establish and strengthen institutional biomedical research capacity in IDeA-eligible states through three sequential 5-year phases.